Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Acq. announced
Inv. presentation
Filed Chapter 11
Codiak BioSciences, Inc. (CDAK) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/27/2023 8-K Filed for Chapter 11
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process CAMBRIDGE, Mass., March 27, 2023 — Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects to consummate a sale of the entire business or its core a..."
11/03/2022 8-K Quarterly results
08/30/2022 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits  Interactiv...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring"
08/04/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
11/30/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Codiak BioSciences Announces FDA Clearance of IND for exoASO ™ -STAT6; Patient Dosing Expected 1H 2022 - Codiak's first engineered exosome therapeutic candidate for systemic administration - - Single agent anti-tumor effect observed in preclinical models via macrophage reprogramming - - Phase 1 trial will evaluate safety, tolerability, biomarkers and preliminary antitumor activity of exoASO-STAT6 in hepatocellular carcinomas - CAMBRIDGE, Mass., November 30, 2021 — Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug Application for exoASO-STAT6. exoASO-STAT6 is Codiak's..."
11/17/2021 8-K Investor presentation
Docs: "Codiak Reports Positive Initial Data for exoSTING ™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts - exoSTING resulted in localized STING pathway activation and dose-dependent immune activation - - Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and distal non-injected lesions - - Data on objective response rate and recommended Phase 2 dose selection for expansion anticipated 1H 2022 - - Codiak to host conference call and webcast today at 8:00 am ET - CAMBRIDGE, Mass., November 16, 2021 — Codiak BioSciences, Inc. , a clinical-sta...",
"Presentation, by Codiak BioSciences, Inc"
11/16/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
11/04/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, by and between Codiak BioSciences, Inc. and Jefferies LLC"
11/04/2021 8-K Quarterly results
Docs: "Codiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational Progress"
11/02/2021 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish"
10/07/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/21/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/18/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/05/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report August 5, 2021 Codiak BioSciences, Inc. Delaware 001-39615 47-4926530 35 CambridgePark Drive, Suite 500 Cambridge, MA 02140 949-4100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the E...",
"Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress"
07/06/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report July 6, 2021 Codiak BioSciences, Inc. Delaware 001-39615 47-4926530 35 CambridgePark Drive, Suite 500 Cambridge, MA 02140 949-4100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exc..."
06/23/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/08/2021 8-K Quarterly results
03/26/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
01/26/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 20, 2021 Codiak BioSciences, Inc. Delaware 001-39615 47-4926530 35 CambridgePark Drive, Suite 500 Cambridge, MA 02140 949-4100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under t..."
12/30/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 30, 2020 Codiak BioSciences, Inc. Delaware 001-39615 47-4926530 35 CambridgePark Drive, Suite 500 Cambridge, MA 02140 949-4100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under ...",
"Codiak Reports Positive Initial Phase 1 Results for exoIL-12 ™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers - exoIL-12 resulted in no local or systemic treatment-related adverse events - - Local administration of exoIL-12 demonstrated no systemic exposure to IL-12 - - Dose selection data and advancement into multi-dose study in cutaneous T cell lymphoma patients anticipated in Q1 2021 - CAMBRIDGE, Mass., December 30, 2020 — Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the primary objectives were met in the initial part of its Phase 1 trial, which evaluated a single ascending dose of exoIL-12 in healthy volu..."
11/20/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report November 19, 2020 Codiak BioSciences, Inc. Delaware 001-39615 47-4926530 35 CambridgePark Drive, Suite 500 Cambridge, MA 02140 949-4100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under th...",
"Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy